192 related articles for article (PubMed ID: 31472458)
21. Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations.
Curley P; Hobson JJ; Liptrott NJ; Makarov E; Al-Khouja A; Tatham L; David CAW; Box H; Neary M; Sharp J; Pertinez H; Meyers D; Flexner C; Freel Meyers CL; Poluektova L; Rannard S; Owen A
Pharmaceutics; 2023 Jun; 15(7):. PubMed ID: 37514020
[TBL] [Abstract][Full Text] [Related]
22. Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.
Castillo-Mancilla JR; Coyle RP; Coleman SS; Morrow M; Gardner EM; Zheng JH; Ellison L; Bushman LR; Kiser JJ; MaWhinney S; Anderson PL
AIDS Res Hum Retroviruses; 2020 Mar; 36(3):173-175. PubMed ID: 31204866
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and anti-retroviral activity of O,O'-bis(3'-azido-2',3'-dideoxythymidin-5'-yl) phosphoramidate derivatives.
Kers I; Stawiński J; Girardet JL; Imbach JL; Périgaud C; Gosselin G; Aubertin AM
Nucleosides Nucleotides; 1999 Oct; 18(10):2317-25. PubMed ID: 10616733
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of aryl phosphoramidate prodrugs of fosfoxacin and its derivatives.
Munier M; Tritsch D; Lièvremont D; Rohmer M; Grosdemange-Billiard C
Bioorg Chem; 2019 Aug; 89():103012. PubMed ID: 31174039
[TBL] [Abstract][Full Text] [Related]
25. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
26. Emtricitabine, a new antiretroviral agent with activity against HIV and hepatitis B virus.
Saag MS
Clin Infect Dis; 2006 Jan; 42(1):126-31. PubMed ID: 16323102
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and anti-herpetic activity of phosphoramidate ProTides.
Maiti M; Persoons L; Andrei G; Snoeck R; Balzarini J; Herdewijn P
ChemMedChem; 2013 Jun; 8(6):985-93. PubMed ID: 23606629
[TBL] [Abstract][Full Text] [Related]
28. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection.
Mu Y; Pham M; Podany AT; Cory TJ
Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507
[No Abstract] [Full Text] [Related]
29. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
[TBL] [Abstract][Full Text] [Related]
30. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Pyles RB; Guthrie KM; Dawson L; Olive TJ; Butkyavichene I; Churchman SA; Cortez JM; Fanter R; Gunawardana M; Miller CS; Yang F; Rosen RK; Vargas SE; Baum MM
PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
[TBL] [Abstract][Full Text] [Related]
31. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate.
Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ
AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652
[TBL] [Abstract][Full Text] [Related]
32. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment.
Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S
AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045
[TBL] [Abstract][Full Text] [Related]
33. Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: structural determinants for in vitro activity and QSAR.
Siddiqui AQ; McGuigan C; Ballatore C; Zuccotto F; Gilbert IH; De Clercq E; Balzarini J
J Med Chem; 1999 Oct; 42(20):4122-8. PubMed ID: 10514282
[TBL] [Abstract][Full Text] [Related]
34. Quantitation of intracellular triphosphate of emtricitabine in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.
Darque A; Valette G; Rousseau F; Wang LH; Sommadossi JP; Zhou XJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2245-50. PubMed ID: 10471573
[TBL] [Abstract][Full Text] [Related]
35. A year-long extended release nanoformulated cabotegravir prodrug.
Kulkarni TA; Bade AN; Sillman B; Shetty BLD; Wojtkiewicz MS; Gautam N; Hilaire JR; Sravanam S; Szlachetka A; Lamberty BG; Morsey BM; Fox HS; Alnouti Y; McMillan JM; Mosley RL; Meza J; Domanico PL; Yue TY; Moore G; Edagwa BJ; Gendelman HE
Nat Mater; 2020 Aug; 19(8):910-920. PubMed ID: 32341511
[TBL] [Abstract][Full Text] [Related]
36. Patient-reported outcomes in virologically suppressed, HIV-1-Infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF.
Hodder SL; Mounzer K; Dejesus E; Ebrahimi R; Grimm K; Esker S; Ecker J; Farajallah A; Flaherty JF;
AIDS Patient Care STDS; 2010 Feb; 24(2):87-96. PubMed ID: 20156091
[TBL] [Abstract][Full Text] [Related]
37. Phosphoramidate and phosphate prodrugs of (-)-beta-D-(2R,4R)-dioxolane-thymine: synthesis, anti-HIV activity and stability studies.
Liang Y; Narayanasamy J; Schinazi RF; Chu CK
Bioorg Med Chem; 2006 Apr; 14(7):2178-89. PubMed ID: 16314108
[TBL] [Abstract][Full Text] [Related]
38. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
[TBL] [Abstract][Full Text] [Related]
39. A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.
Benson CA; van der Horst C; Lamarca A; Haas DW; McDonald CK; Steinhart CR; Rublein J; Quinn JB; Mondou E; Rousseau F;
AIDS; 2004 Nov; 18(17):2269-76. PubMed ID: 15577539
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological activity of novel 5-fluoro-2'-deoxyuridine phosphoramidate prodrugs.
Freel Meyers CL; Hong L; Joswig C; Borch RF
J Med Chem; 2000 Nov; 43(22):4313-8. PubMed ID: 11063625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
